600329 Stock Overview
Produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥33.36 |
| 52 Week High | CN¥39.05 |
| 52 Week Low | CN¥23.40 |
| Beta | 0.78 |
| 11 Month Change | -3.05% |
| 3 Month Change | 15.39% |
| 1 Year Change | -1.80% |
| 33 Year Change | 42.20% |
| 5 Year Change | 153.50% |
| Change since IPO | 138.29% |
Recent News & Updates
Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?
Oct 27
Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge
Oct 08Recent updates
Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?
Oct 27Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge
Oct 08Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio
Jul 26Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Jul 05Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)
Apr 18Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Mar 18Shareholder Returns
| 600329 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.4% | -4.0% | -3.9% |
| 1Y | -1.8% | -5.3% | 4.0% |
Return vs Industry: 600329 exceeded the CN Pharmaceuticals industry which returned -5.3% over the past year.
Return vs Market: 600329 underperformed the CN Market which returned 4% over the past year.
Price Volatility
| 600329 volatility | |
|---|---|
| 600329 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.5% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600329 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600329's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,619 | Lei Wang | www.jydrt.com.cn |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; and biochemical pharmaceutical products, as well as wholesale and retail sale of medicines. Its products include Suxiao Jiuxin Pills, Jingwanhong Ointment, Biqi Capsules, Shunaoxin Dropping Pills, Zilongjin Tablets, Qingfei Xiaoyan Pills, Huoxiangzhengqi Soft Capsules, Tongmai Yangxin Pills, Weichangan Pills, Qingyan Dropping Pills, Haima Bushen Pills, Angong Niuhuang Pills, Niuhuang Qingxin Pills, Qinggong Shoutao Pills, etc. The company also engages in pharmaceutical commercial logistic services; pharmaceuticals retail; chemical raw materials and preparations; and biomedicine.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Fundamentals Summary
| 600329 fundamental statistics | |
|---|---|
| Market cap | CN¥22.34b |
| Earnings (TTM) | CN¥932.37m |
| Revenue (TTM) | CN¥8.04b |
27.6x
P/E Ratio3.2x
P/S RatioIs 600329 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600329 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.04b |
| Cost of Revenue | CN¥4.30b |
| Gross Profit | CN¥3.74b |
| Other Expenses | CN¥2.81b |
| Earnings | CN¥932.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 46.50% |
| Net Profit Margin | 11.60% |
| Debt/Equity Ratio | 19.8% |
How did 600329 perform over the long term?
See historical performance and comparison